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post-translational protein modifi cation 
resulting in different structural isoforms 
[7, 8]. In addition to glycosylation, enzy-
matic cleavage of C-terminal lysines 
contributes to the heterogeneity of mono-
clonal antibodies [9]. The formation and 
nature of these structural variants are 
highly sensitive to manufacturing pro-
cesses, and changes in any of the manu-
facturing steps may lead to differences in 
the specifi c isoforms that are present.
Differences in glycosylation profi le and 
cleavage of C-terminal lysines can affect 
the tertiary (i.e. the overall 3-dimensional 
shape of the protein) and quaternary 
structure (i.e. interaction of protein sub-
units) of a biological agent [10]. Thus, it 
is important to characterize the key qual-
ity attributes (e.g. physicochemical and 
structural features) of a biological drug 
substance and constantly monitor these 
during production, using robust analytical 
methods to help assure product consis-
tency, including the pattern and percent-
age of each structural isoform.
Consistency of adalimumab 
manufacturing
A recent product quality analysis evalu-
ated 544 total batches of adalimumab 
manufactured between 2000 and 2013 [6]. 
Molecular charge, as measured by the 
presence of acidic species and C-terminal 
lysine variants, and glycosylation pattern 
were the key properties used to demon-
strate the comparability and consistency 
of the production process, see Table 1, [6]. 
The quantitation of the sum and overall 
lysine variant profi le demonstrated con-
sistency between the batches over the 
course of 13 years [6]. Additionally, a high 
degree of consistency for the sum of 
lysine variants was observed between 5 
different bioreactor sizes used for produc-
tion [6]. Comparison of the identity and 
quantity of adalimumab oligosaccharides 
profi le from 381 different batches indi-
cated a high level of consistency between 
the batches over time and through-
out the production scale changes, see 
Table 1, [6]. Furthermore, the consistency 
of the charged species and glycosylation 
patterns of adalimumab was supported 
by biological data, demonstrating that 
its interaction with and intrinsic binding 
affi nity for soluble TNF-α ligand remained 
stable during this period [6].
Importance of consistency of adalim-
umab manufacturing
It has been clearly demonstrated that the 
manufacturing process for adalimumab 
produced a consistent product over an 
extended (> 10 years) period of time [6], 
even as necessary changes to the manu-
facturing processes and production scale 
were introduced. It is paramount for 
manu facturers of biological products to 
maintain tight control of the drug sub-
stance and its production to ensure effec-
tive and safe use in patients. In the case 
of adalimumab, the need for a high level 
of consistency and product quality may 
be magnifi ed, in part, because of the 
diverse patient populations being treated, 
and the underlying etiologies of the dif-
ferent chronic immune-mediated infl am-
matory diseases for which adalimumab is 
indicated.
Variations in glycosylation pattern or other 
post-translational modifi cations can result in 
subtle changes in the conformation of a bio-
logical that can potentially alter its solubility, 
stability, effi cacy, or immunogenicity [8, 10]. 
Studies have demonstrated that variations in 
glycosylation can lead to signifi cant changes 
in the circulating levels of the biological sub-
Introduction
Biological therapeutics are highly sensitive 
to formation of structural variants during 
manufacturing processes. These structural 
variants can affect clinical performance. 
Here, we review important recently pub-
lished technical data on adalimumab con-
sistency and manufacturing experience 
from a clinical perspective.
Adalimumab
Adalimumab (Humira®, AbbVie, Inc) is a 
recombinant human immunoglobulin (Ig) 
G1 antitumour necrosis factor-α (TNF- α) 
monoclonal antibody originally approved 
for the treatment of rheumatoid arthri-
tis in the US in 2002, and subsequently 
approved for the management of Crohn’s 
disease, ulcerative colitis, plaque psoriasis, 
psoriatic arthritis, ankylosing spondylitis, 
juvenile idiopathic arthritis, and hidradeni-
tis suppurativa [1]. Since its approval in the 
US, many other countries have approved 
its use for multiple indications [2, 3].
Complex nature of biologicals
As is the case for many biologicals, adali-
mumab is a large glycoprotein that is a 
heterogenous mixture of structural iso-
forms [4-6]. Glycosylation, the addition 
of sugar residues by the host organism 
during manufacturing process, is a major 
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sequent to altered pharmacokinetics, and 
alter its distribution to specifi c tissues and 
organs [7]. For example, therapeutic IgGs 
containing high-mannose glycans in the Fc 
region are cleared more rapidly in humans 
than other glycan forms [11]. Furthermore, 
some residues, such as galactose-containing 
glycans, can induce conformational changes 
that expose portions of the mole cule previ-
ously hidden from the immune system and 
possibly lead to an antigenic response [8, 12].
Immunogenicity is a primary area of safety 
for biologicals and is often carefully moni-
tored [13]. Immunogenic response results 
in the development of non-neutralizing 
(sometimes termed binding) or neutralizing 
anti-drug antibodies against the biological 
product. Non-neutralizing antibodies bind 
biological molecules on sites unrelated to 
target binding; however, non-neutralizing 
antibodies can reduce drug bioavailabil-
ity through increased clearance, indirectly 
decreasing effi cacy [14]. Neutralizing anti-
bodies, on the other hand, bind biologicals 
on sites that interfere with target binding, 
reducing or sometimes halting effi cacy  [14]. 
Immunogenic response can have a number 
of outcomes ranging from adverse events, 
such as hypersensitivity reactions (i.e. 
reactions to drug administration), to reduced 
serum levels and neutralized activity of the 
biological; in other cases, it has no apparent 
effect on effi cacy or safety of the product [9].
The presence of anti-adalimumab anti-
bodies after treatment varied between 
3% and 28% among different disease 
states, see Table 2, [1, 2, 15-17]. Because 
the measured incidence of anti-drug and 
neutralizing antibodies is highly depen-
dent on the assay type and because mul-
tiple factors (such as assay sensitivity and 
specifi city, methodology, disease state, 
sample handling, and timing of sample 
collection) affect the results, comparison 
of the incidence of antibodies between 
studies or between different biologicals is 
misleading [14]. Nevertheless, presence of 
anti-adalimumab antibodies, even at mod-
erate concentration, can impact patients’ 
response to treatment. In studies of rheu-
matoid arthritis and Crohn’s disease, anti-
adalimumab antibodies were associated 
with lower adalimumab serum levels 
[16, 17]. Furthermore, a higher percent-
age of treatment non-responders had anti-
adalimumab antibodies compared with 
treatment responders in one study [16]. 
Because adalimumab is used for the treat-
ment of patients with chronic immune-
mediated infl ammatory diseases, it may 
be important to establish and maintain 
a long-term immunologic equilibrium in 
patients treated with adalimumab. By pro-
viding a consistent product with key attri-
butes maintained within a narrow window 
of variability from batch to batch, the risk 
of potential changes in the antigenicity of 
adalimumab over time is minimized.
Changes to a tightly controlled manufactur-
ing process that may lead to variations in 
epitopes could disrupt the immunologically 
tolerated state of a patient to their initial 
therapeutic. Likewise, switching a stable 
patient to a related but different molecule, 
as would be the case when using a bio-
similar of the initial therapeutic made by a 
different manufacturer, may increase anti-
genicity. Well-established mechanisms of 
tolerance include clonal deletion, recep-
tor editing, clonal anergy, blockade of 
memory response, and competitive toler-
ance [18]. Overall, immune responses are 
unpredictable and immunological response 
to treatment with biological therapies, such 
as adalimumab, can vary greatly between 
individual patients and disease states. 
Furthermore, patients can develop anti-drug 
antibodies with clinical impact ranging from 
no effects to secondary loss of response. 
Table 1: Manufacturing consistency of Adalimumab
Attribute Mean SD Relevance References
Glycans
Agalactosylfucosylated 
biantennary 
oligosaccharides 
(G0F + G0F-GlcNAc)
74.28 1.75 Glycoforms containing terminal 
N-acetylglucosamine residues 
may activate pattern recognition 
receptors, such as mannan bind-
ing lectin and mannose receptor. 
Afucosylation enhances affi nity 
to FcγRIIIa, ADCC activity and 
in vivo effi cacy.
[12, 20-22]
Galactosyl-containing 
glycans (G1F + G2F)
18.45 1.80 Galactosylation may affect IgG1 
conformation, bioavailability and 
activity; highly galactosylated 
mAbs show increased in vitro 
C1q-binding and CDC activity, 
increased FcγRII and Fcγ RIIIa 
binding, and enhanced ADCC 
activity.
[12, 23-27]
Mannose-containing 
glycans (M5 + M6)
7.29 0.86 High mannose glycans may 
increase ADCC activity, stimulate 
enhanced clearance of mAbs, and 
elicit immunogenicity.
[11, 24, 
28, 29]
Charge variants
C-terminal lysines 
(sum of K0, K1, K2)
86.33 1.10 Alterations in acidic species show 
decreased binding affi nity and 
potency, reduced half-life, and 
immunogenicity. C-terminal lysine 
processing may affect comple-
ment C1q binding and thus 
effector functions such as CDC.
[30-35]
Acidic species (AR1) 2.41 0.52
Acidic species (AR2) 10.20 0.71
Glycan mapping of adalimumab (Humira®, AbbVie, Inc) proceeded via assessment of oligosaccharides (G0F + G0F-GlcNAc; 
G1F + G2F; M5 + M6) using NP-HPLC to separate fl uorescent-labelled glycan species. Adalimumab batches (n = 381) pro-
duced from 2001 to 2013 (scale ranges from 3,000 to 20,000 liters) were analysed. The relative amount of each glycan species 
was calculated as a per cent of total area from NP-HPLC chromatograms.
Charge variant profi les of adalimumab were analysed using WCX-HPLC on batches (n = 525) that derived from manufacturing 
scales ranging from 3,000 to 20,000 liters over the time period 2001–2013. The relative amounts of the acidic species (AR1 and 
AR2) and c-terminal lysine isoforms (K0, K1, K2) was calculated from the chromatograms as a per cent of total area.
ADCC: antibody-dependent cell-mediated cytotoxicity; AR: acidic region; C1: complement component 1; CDC: complement 
dependent cytotoxicity; FcγR: Fc gamma receptor; G0F: agalactosyl fucosylated biantennary glycan; G0F-GlcNAc: agalactosyl 
fucosylated biantennary glycan without a terminal N-acetyl glucosamine; G1F: galactosylated fucosylated biantennary glycan; 
G2F: di-galactosylated fucosylated biantennary glycan; Ig: immunoglobulin; K: lysine; M: mannose; mAb: monoclonal anti-
body; NP-HPLC: normal phase high-performance liquid chromatography; SD: Standard Deviation.
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The immune response to adalimumab is a 
dynamic process in which anti-drug anti-
bodies can develop and then disappear 
over time. Whether a stable patient who 
undergoes a non-medical switch between 
an initial therapeutic and its biosimilar 
(which would expose the immune system 
to distinct antigens) can maintain or sub-
sequently regain tolerance is unknown. 
Appropriate investigation is recommended 
because of the paucity of available clinical 
data that pertain to the phenomenon of 
switching [19]. Importantly, data regarding 
the use of multiple biosimilar molecules in 
a single patient are also lacking.
Conclusions
The comparison of over 500 batches of 
adalimumab from 2000 to 2013 demon-
strated that the key physicochemical and 
functional quality attributes of adalim-
umab have remained within a narrow 
range during this long time frame. Thus, 
patients who have been or are currently 
treated with adalimumab have received 
a consistent product during the course of 
their treatments, have developed immune 
tolerance to the antigens consistently 
delivered, and ultimately have achieved 
stability in terms of clinical response.
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